Skip to main content

Gene Logic Shareholders OK Sale of Genomic Business, Name Change

NEW YORK (GenomeWeb News) - Gene Logic said today that its shareholders have approved the sale of its genomic assets to Ocimum Biosolutions, as well as its transformation into a drug repositioning firm with the new name of Ore Pharmaceuticals.
Gene Logic announced its plans to change its focus and its brand in late October, after it struck a deal with Ocimum to sell its genomics business for $10 million.
Ocimum will own the Gene Logic name. The company's stock will continue to trade on the Nasdaq exchange under a new ticker symbol, ORXE.
"As a drug repositioning and development company, our sole purpose is to supply the demand of pharmaceutical companies for product innovation to enrich their development pipelines," said Gene Logic's CEO, Charles Dimmler, in a statement.
The company said it expects to close the sale of its genomics business to Ocimum by the end of this week.
The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.